A new prostaglandin E1 analogue (TFC-612) prevents a decrease in motor nerve conduction velocity in streptozocin-diabetic rats

• Published in: Biochemical and biophysical research communications Vol. 150; no. 1; pp. 225 - 230
• Main Authors: Yasuda, Hitoshi, Sonobe, Masanobu, Hatanaka, Ikuo, Yamashita, Makio, Miyamoto, Yasufumi, Terada, Masahiko, Amenomori, Masanori, Kikkawa, Ryuichi, Shigeta, Yukio, Motoyama, Yukio, Saito, Noriyuki
• Format: Journal Article
• Language: English
• Published: San Diego, CA Elsevier Inc 15.01.1988; Elsevier
• Subjects: Alprostadil - analogs & derivatives; Alprostadil - therapeutic use; Animals; Biological and medical sciences; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - physiopathology; Diabetic Neuropathies - drug therapy; Diabetic Neuropathies - physiopathology; Fundamental and applied biological sciences. Psychology; Inositol - metabolism; Insulin - therapeutic use; Male; Motor Neurons - physiology; Neural Conduction; Prostaglandins E, Synthetic; Prostaglandins. Arachidonic acid metabolites; Rats; Rats, Inbred Strains; Sciatic Nerve - physiopathology; Sorbitol - metabolism; Vertebrates: endocrinology
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/0006-291X(88)90509-8

A new prostaglandin E1 analogue (TFC-612) was orally given to streptozocin-diabetic rats for 4 weeks after the induction of diabetes and its effects on motor nerve conduction velocity were studied. The compound significantly prevented a decrease of the velicity but did not reverse abnormal sorbitol and myo-inositol contents of the sciatic nerve. The results suggest that TFC-612 has a potent effect on diabetic nerve dysfunction via other mechanism than the correction of sorbitol and myo-inositol metabolisms and could be a potential compound for therapy of diabetic polyneuropathy.